Dallas, Texas, United States The main office of represented VC is situated in the Dallas. The company was established in North America in United States.
The fund is constantly included in less than 2 deals per year. The higher amount of exits for fund were in 2019. The usual things for fund are deals in the range of 10 - 50 millions dollars. The top activity for fund was in 2010. This Tichenor Ventures works on 14 percentage points more the average amount of lead investments comparing to the other organizations.
The standard case for the fund is to invest in rounds with 4-5 partakers. Despite the Tichenor Ventures, startups are often financed by The Column Group, Prospect Venture Partners, Rho Ventures. The meaningful sponsors for the fund in investment in the same round are The Column Group, Prospect Venture Partners, Auven Therapeutics. In the next rounds fund is usually obtained by Topspin Partners, HBM Healthcare Investments AG, The Column Group.
Among the most popular portfolio startups of the fund, we may highlight NGM Biopharmaceuticals, Kolltan Pharmaceuticals. Besides, a startup needs to be aged 4-5 years to get the investment from the fund. Among the most popular fund investment industries, there are Medical, Therapeutics. The fund has no exact preference in a number of founders of portfolio startups. For fund there is a match between the country of its foundation and the country of its the most frequent investments - United States.
Related Funds
Funds with similar focus
| Fund Name | Location |
| Auriga Capital Management | New York, New York, United States |
| Centre Palisades Ventures | California, Los Angeles, United States |
| Daiwa Food & Agriculture | Japan, Tokyo |
| Draft Ventures | California, San Francisco, United States |
| Hulic | Japan, Tokyo |
| KIN Capital | Chengdu, China, Sichuan |
| Lightheart Management Partners | British Columbia, Canada, Vancouver |
| Serena | France, Ile-de-France, Paris |
| SnapChat | California, United States, Venice |
| St. Petersburg Downtown Partnership | - |
Notable deals
| Company | Industry | Round Size | Date | Investors | Location |
OS Therapies | $6M | 20 Apr 2021 | Virginia, United States | ||
NGM Biopharmaceuticals | $50M | 18 Jul 2013 | South San Francisco, California, United States | ||
NGM Biopharmaceuticals | $55M | 15 Mar 2010 | South San Francisco, California, United States | ||
Kolltan Pharmaceuticals | $10M | 20 Jan 2010 | New Haven, Connecticut, United States | ||
Kolltan Pharmaceuticals | $5M | 12 Oct 2009 | New Haven, Connecticut, United States | ||
Kolltan Pharmaceuticals | $40M | 31 Jul 2008 | New Haven, Connecticut, United States |
1. You post comments at your own choice and risk. You bear the whole responsibility,related to their substance, content and the fact of publication. We shall not bear anyliability in respect of such comments.
2. While commenting, you shall use only actual, truthful and confirmed data. In thesame time you shall not use vulgar, abusive or defamatory language as well as expresshatred or call to violence or cruelty.
3. We do not intend to delete any comments on the website unless within our “noticeand take down” procedure.
4. We can moderate comments at any time.
5. While commenting, you are under the rule of our website’s terms of use and privacypolicy.
6. We retain our right to delete any comment or any other content of the website at ourwill in case we know or suppose such content is illegal or breaches any lawful right.
Review
- No reviews are submitted yet.
Sign up and get access to full fund profile and advanced analysis.
Full teamIndustries heatmapStages heatmapGeorgaphy breakdownCoinvestorsPortfolio analysisPerformance indexesLatest highlights
Unlock all data Latest deals
| Company | Industry | Round Size | Date | Investors | Location |
OS Therapies | $6M | 20 Apr 2021 | Virginia, United States | ||
NGM Biopharmaceuticals | $50M | 18 Jul 2013 | South San Francisco, California, United States | ||
NGM Biopharmaceuticals | $55M | 15 Mar 2010 | South San Francisco, California, United States | ||
Kolltan Pharmaceuticals | $10M | 20 Jan 2010 | New Haven, Connecticut, United States | ||
Kolltan Pharmaceuticals | $5M | 12 Oct 2009 | New Haven, Connecticut, United States | ||
Kolltan Pharmaceuticals | $40M | 31 Jul 2008 | New Haven, Connecticut, United States |
